Impact Therapeutics-B (07630.HK) intends to repurchase up to HK$100 million of the Company's H shares.

Zhitong Finance APP News, IMPACT Therapeutics-B (07630.HK) announced that the Board has resolved to repurchase the Company's H shares on the public market of The Stock Exchange of Hong Kong Limited from time to time, pursuant to the general mandate approved by the Company's shareholders and granted to the Company's directors at the annual general meeting held on June 25, 2026, with an aggregate amount not exceeding HK$100 million (including transaction costs such as brokerage commissions and stamp duty).